Study: Lee 2023, Cochrane Database of Systematic Reviews

Interventions for people with type 2 diabetes mellitus fasting during Ramadan

Citation

Lee SWH, Chen WS, Sellappans R, Md Sharif SB et al (2023). Cochrane Database of Systematic Reviews. PubMed id 37435938.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Fasting in Ramadan with diabetes or sickle cell Tier B thin

    B 5,359 Muslims with type 2 diabetes fasting in Ramadan, in 17 randomised trials of drugs or education (n=17 trials (5,359 people))

    Cochrane systematic review of randomised trials, GRADE.

    Every trial had at least one high-risk domain for bias. Dipeptidyl-peptidase-4 inhibitors may cause less hypoglycaemia than sulphonylureas (low-certainty evidence). The evidence on serious hypoglycaemia, other harms and HbA1c was very uncertain, and no deaths were reported. Trials compared medicines; none tested whether fasting itself is safe.

    As recorded in this card: Lee SWH, Chen WS, Sellappans R, Md Sharif SB et al (2023), Cochrane Database of Systematic Reviews, [review]

    Note: My copy of the abstract is cut before the education and insulin results and does not list the countries; strength is therefore taken at the lower reading.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.